Candida auris is an emerging species of pathogenic fungus/yeast that has caused outbreaks in healthcare settings in the United States. This organism is often resistant to most common antifungal drugs, which makes infections difficult to treat and can lead to fatalities. Effective diagnostic tools and surveillance practices will help to identify and minimize outbreaks.1

Effective April 24, 2023, ARUP will offer a new molecular screening test, Candida auris by PCR (3006370).

Molecular testing offers a fast and effective tool to screen individuals who may be colonized with Candida auris but don’t have invasive infection. This assay can help healthcare facilities’ surveillance programs to identify risk and take appropriate measures to prevent the spread of Candida auris.


Updated: April 24, 2023

ARUP’s In-House Tests for Candida auris

Which test can be ordered to identify Candida auris?

Effective April 24, 2023, the following molecular screening test will be available:


Candida auris by PCR

Culture tests are also available to rule out Candida auris.


Fungal Culture

*When ordering Fungal Culture (0060149), if Candida auris is suspected, add an order comment specifically requesting that Candida auris be ruled out if the source of the culture is a nonsterile site (e.g., urine or respiratory sources).
Example order comment: “Specimen source ______. Rule out Candida auris.”
This comment will help to ensure that yeast resembling Candida detected from a nonsterile site will be identified to the species level.

What are the specimen requirements for Candida auris by PCR (3006370)?

The following are the specimen requirements:

Acceptable specimens
  • Skin swab (placed in Eswab transport media (ARUP supply #45877)
  • Urine
  • Bronchoalveolar lavage
  • Sputum

*For fluid specimens, 1 mL (minimum, 0.5 mL) is required.


Ambient: 14 days; refrigerated: 14 days; frozen: 14 days

Turnaround time

1–3 days

NY approval


What are the specimen requirements for Fungal Culture (0060149)?

Refer to the laboratory test directory for Fungal Culture (0060149) specimen requirements.

Please provide the specimen source in the order comments.

Example order comment: “Specimen source ______.”  Rule out Candida auris.”

When submitting an isolate, which test should I order to rule out Candida auris?

Order Fungal (Mold/Yeast) Identification (0060163).

Please provide the specimen source and an order comment asking that Candida auris be ruled out.

Example order comment: “Specimen source ______.”  Rule out Candida auris.”

How is public health reporting handled?

Candida auris is a reportable organism. ARUP will report as required by state laws and regulations; this meets our reporting requirements as the performing laboratory. This does not cover reporting that may or may not be required by other healthcare providers. ARUP does not maintain a list of reporting requirements for providers, so we are not able to provide guidance on provider/client reporting.

Susceptibility Testing

Which test should I order to determine drug resistance of Candida auris isolates?

Drug resistance is a known issue associated with Candida auris infections. Susceptibility testing should be considered when an invasive infection is suspected. Susceptibility testing is not generally indicated for patients colonized with Candida auris

If susceptibility testing is indicated,please order Antimicrobial Susceptibility - Fungal (Yeast and Molds) (2009257). Please indicate the source of the isolate.


  • Centers for Disease Control and Prevention. Candida auris. (accessed on April 21, 2023)

Additional Resources:

If you have additional questions, please contact ARUP Client Services and use keyword: Candida auris.